The stock of Dermata Therapeutics Inc. (NASDAQ:DRMA) increased by $0.26 on Wednesday to $1.27, up 25.75 percent. The last five days have seen an average of 478,451 shares of common stock traded. 1 time new highs were reached in the current year, with a fall of -$5.3035. The average number of shares traded over the last 20 days was 149,863, while the average volume over the last 50 days totaled 138,275.
DRMA stock appreciated 0.01% since last month. On 08/29/23, the company’s shares reached a one-month low of $0.9369. The stock touched a high of $13.12 on 01/03/23, after rallying from a low of $0.94 in 52 weeks. The price of DRMA stock has declined by -80.59% or -$5.3035 this year, reaching a new high 1 time. Still, the stock price is down -90.32% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
For the three months ended June 29, Dermata Therapeutics Inc.’s quick ratio was 12.80, while its current ratio was 12.80, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $64000.0 and revenue of $9.68 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. DRMA’s return on assets (ROA) during the last 12 months has been -94.70%. In the meantime, the return on equity (ROE) for the last 12 months was -108.60%.
Earnings Surprise
According to Dermata Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. It was predicted that Dermata Therapeutics Inc.’s quarterly earnings would be -$0.63, but it ended up being -$0.92, beating the consensus by 31.50%. EBITDA was -$1.73 million for the quarter. Equity owned by shareholders amounts to $3.19 million.
Technical Picture
Here’s a quick look at Dermata Therapeutics Inc.’s (DRMA) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 57.81%, suggesting the stock is Neutral, with a 119.94% historical volatility rate.
The stochastic %K and %D were 36.03% and 18.25% respectively, while the average true range (ATR) was 0.1084. Based on the 14-day stochastic reading of 79.25%, the RSI (14) reading is 50.24%. On the 9-day MACD Oscillator, the stock is at -0.0154, and the 14-day reading is at -0.0373.
Analyst Ratings
Analysts have assigned Dermata Therapeutics Inc. (DRMA) an Buy rating. DRMA is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is DRMA’s price target for the next 12 months?
The current consensus forecast for the stock is between $4.00 and $4.00, with a median target price of $4.00. In analyzing these forecasts, the average price target given by analysts for Dermata Therapeutics Inc. (DRMA) is $4.00.
